0001209191-21-021585.txt : 20210317
0001209191-21-021585.hdr.sgml : 20210317
20210317200305
ACCESSION NUMBER: 0001209191-21-021585
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210315
FILED AS OF DATE: 20210317
DATE AS OF CHANGE: 20210317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Riker Lauren Bullaro
CENTRAL INDEX KEY: 0001545439
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 21752521
MAIL ADDRESS:
STREET 1: C/O PACIRA PHARMACEUTICALS, INC.
STREET 2: 5 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-15
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001545439
Riker Lauren Bullaro
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
0
1
0
0
Vice President, Finance
Common Stock
2021-03-15
4
M
0
1520
10.81
A
14701
D
Common Stock
2021-03-15
4
S
0
1520
73.28
D
13181
D
Common Stock
2021-03-17
4
M
0
2000
10.81
A
15181
D
Common Stock
2021-03-17
4
S
0
2000
70.01
D
13181
D
Stock Option (Right to Buy)
10.81
2021-03-15
4
M
0
1520
0.00
D
2022-06-05
Common Stock
1520
16300
D
Stock Option (Right to Buy)
10.81
2021-03-17
4
M
0
2000
0.00
D
2022-06-05
Common Stock
2000
14300
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.03 to $73.50, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.00 to $70.04, inclusive.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
/s/ Kristen Williams, Attorney-in-Fact
2021-03-17